Cellebrite DI Ltd.
Cellebrite is an Israeli software company headquartered in Petah Tikva. It provides digital investigative and intelligence solutions to public and private sector customers, including law enforcement, defense and intelligence agencies, enterprises and service providers. Its platform supports the collection, extraction, decoding, review, analysis, sharing and management of digital evidence from devices and other sources. Cellebrite’s products include the Inseyets digital forensics suite; Guardian tools for evidence management and sharing; Pathfinder analytics software; and Corellium virtualization products for mobile security research and application testing. It also offers training and certification, and expert digital forensics services. The company earns money primarily through software subscriptions, which can be delivered as SaaS or deployed on customer premises, as well as through professional services.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Cellebrite (CLBT) reported Q3 EPS of $0.17, beating estimates by $0.07, but revenue of $149M missed expectations of $150.3M. The stock is up 14% over 3 months but down 34% over 12 months. InvestingPro rates its financial health as 'great performance'.
Cellebrite DI Ltd. (CLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Cellebrite Reports Third-Quarter 2026 Results Third-Quarter ARR Growth of 20% and TTM Free Cash Flow Margin of 31% Net income of $26.7 million; Non-GAAP net income of $45.6 million and adjusted EBITDA of $53.6 million, 36% adjusted EBITDA margin TYSONS CORNER, VA and
Cellebrite (CLBT) appointed Rogerio Rizzi as executive vice president of Corporate Strategy and Development. He will lead the company's strategy and development efforts. No financial targets or results were disclosed.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CLBT (Cellebrite DI Ltd.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent CLBT coverage spans corporate actions, earnings and financial news.
In the last 30 days, CLBT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($136K). The most active reporter was Barter David, Chief Financial Officer, with 1 filing.
EPS beat may drive short‑term buying pressure; revenue miss could temper upside.
Cellebrite posted strong Q3 results and issued guidance that raises its EBITDA outlook, suggesting improved profitability.
The appointment signals a focus on strategic growth but does not provide immediate financial impact.
The insider sale may signal slight negative sentiment but the amount is modest.
The filing reveals a modest passive holding; market impact is expected to be minimal.
AlphAI scores every news story that mentions CLBT with an AI model for sentiment and relevance, and aggregates insider trades from Cellebrite DI Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cellebrite (CLBT) reported Q3 EPS of $0.17, beating estimates by $0.07, but revenue of $149M missed expectations of $150.3M. The stock is up 14% over 3 months but down 34% over 12 months. InvestingPro rates its financial health as 'great performance'.
Cellebrite DI Ltd. (CLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Cellebrite Reports Third-Quarter 2026 Results Third-Quarter ARR Growth of 20% and TTM Free Cash Flow Margin of 31% Net income of $26.7 million; Non-GAAP net income of $45.6 million and adjusted EBITDA of $53.6 million, 36% adjusted EBITDA margin TYSONS CORNER, VA and
Cellebrite (CLBT) appointed Rogerio Rizzi as executive vice president of Corporate Strategy and Development. He will lead the company's strategy and development efforts. No financial targets or results were disclosed.
Barter David (Chief Financial Officer) sold 12,134 shares of Cellebrite DI Ltd. (CLBT) at $11.21 ($0.14M total) on 2026-10-16.
Pertento Partners LLP, Pertento Advisors LLC, and Eduardo Marques each reported a 5.2% passive stake in Cellebrite DI Ltd. (CLBT), owning 13,164,696 shares with shared voting and dispositive power. The shares are directly owned by advisory clients, with no beneficial ownership claimed beyond pecuniary interest.
Cellebrite DI Ltd. shareholders approved CEO Shiven Ramji's pay package, re-elected directors, and re-appointed auditors at their annual meeting on September 24, 2026. 80.9% of shares were represented, per the company's SEC filing.
Cellebrite DI Ltd (NASDAQ: CLBT) plans a corporate reorganization under a new U.S.-based parent company, pending approvals, to streamline operations and unlock shareholder value. GF Value™ estimates CLBT is 31.7% undervalued at $11.23 vs. an intrinsic value of $16.44. The company has a GF Score™ of 81/100, indicating strong fundamentals, but insiders have sold $5.2 million in shares over the past year.
Cellebrite DI Ltd. (CLBT) named CTO Chris Wade to lead Cellebrite Labs, focusing on mobile access, extraction, and decoding research. The move follows the Corellium acquisition, aiming to streamline R&D efforts.
Cellebrite (CLBT) plans to redomicile in the U.S. by mid-2027, pending approvals. The move aims to boost growth in key markets and attract more investors. CEO Shiv Ramji cited strategic benefits, including inclusion in key indices. Details will be shared in SEC filings.
Cellebrite DI (CLBT) announced its Guardian cloud platform received a PROTECTED-level IRAP assessment for Australian public sector use, and launched the C TEK backpack kit for military forensics. These developments could impact contract structures, deployment costs, and long-term demand from government clients. The company projects $787.4M revenue and $122.0M earnings by 2029, implying 15.3% yearly revenue growth. Analysts' fair value estimates range from $12.50 to $15.36, with the current share
